Lessons to be learned from serum biomarkers in psoriasis and IBD - the potential role in SpA

Expert Rev Clin Immunol. 2017 Apr;13(4):333-344. doi: 10.1080/1744666X.2017.1244004. Epub 2016 Oct 21.


Early diagnosis, monitoring of disease activity, prediction of treatment response, and structural outcome remain major challenges in spondyloarthritis (SpA). Biomarkers could play a role in addressing these challenges, but in SpA there is a lack of suitable biomarkers. Areas covered: As SpA is clinically and pathophysiologically closely related to psoriasis and inflammatory bowel disease (IBD), we reviewed in literature, the value of serum biomarkers in these conditions with the aim to find potential candidates for assessing SpA. Expert commentary: Candidates of interest were antimicrobial peptides, including serum human beta defensin-2 (hBD-2) and lipocalin-2 (LCN-2), and class-1 MHC molecule beta2-microglobulin. Since these biomarkers are relevant in psoriasis and/or IBD from a pathophysiological point of view, and may play a role in the pathogenesis of SpA, we recommend further exploration of their value as biomarker in the diagnosis and prognosis of SpA.

Keywords: Spondyloarthritis; biomarkers; inflammatory bowel diseases; psoriasis; serum.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / blood*
  • Early Diagnosis
  • Humans
  • Inflammatory Bowel Diseases / diagnosis*
  • Lipocalin-2 / blood*
  • Prognosis
  • Psoriasis / diagnosis*
  • Spondylitis, Ankylosing / diagnosis*
  • beta 2-Microglobulin / blood*
  • beta-Defensins / blood*


  • Biomarkers
  • DEFB4A protein, human
  • LCN2 protein, human
  • Lipocalin-2
  • beta 2-Microglobulin
  • beta-Defensins